TARRYTOWN, N.Y.--(BUSINESS WIRE)--April 21, 2006--Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX - News) and Wyeth (NYSE: WYE - News) today announced their plan to submit by early 2007 a New Drug Application (NDA) with the U.S. Food and Drug Administration for subcutaneous methylnaltrexone (MNTX) in a new room-temperature formulation. Progenics and Wyeth are developing this improved formulation of subcutaneous MNTX, which does not require refrigeration, to make this drug more convenient for patients and caregivers. The investigational drug MNTX is a peripheral opioid receptor antagonist that is designed to treat rapidly the side effects of opioids without interfering with pain relief. Recently, the second of two pivotal phase 3 clinical studies using the prior formulation demonstrated that MNTX is highly active in treating opioid-induced constipation in patients with advanced illness.
